3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
26
Urinary Bladder Neoplasms
23
Ureteral Neoplasms
8
Urologic Neoplasms
4
Urethral Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Urogenital Neoplasms
2
Peripheral Nervous System Diseases
2
Neoplasm Metastasis
2
Muscle Invasive Bladder Urothelial Carcinoma
2
Metastatic Urothelial Cancer
2
Carcinoma, Renal Cell
2
Advanced Bladder Cancer
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urachal adenocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
1
Metastatic Castration-resistant Prostate Cancer
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Cystectomy
2
Cisplatin
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
tislelizumab
1
relatlimab
1
enzalutamide
1
enfortumab vedotin
1
durvalumab
1
Water
1
Urinary Diversion
1
Standard of Care
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Multiparametric Magnetic Resonance Imaging
1
Microscopy
1
Immunonutrition Diet
1
Immune Checkpoint Inhibitors
1
Gels
1
Fluorouracil
1
Docetaxel
1
Cystoscopy
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Diseases
×
enfortumab vedotin
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled